Loading clinical trials...

UNKNOWN

Ultrasound Abnormalities of the Salivary Glands in Primary Sjögren's Syndrome According to the Duration of the Disease

Ultrasound Abnormalities of the Salivary Glands in Primary Sjögren's Syndrome

NCT04212572•University Hospital, Brest

Summary

Salivary gland ultrasonography is identified as a valuable diagnostic tool and potential criteria item for disease classification of sjögren's syndrome and evaluate evolution of parenchyma. The investigators have to include 242 patients. The objective is to evaluate the modification of ultrasonographic abnormalities according to disease in primary Sjögren syndrome.

Eligibility

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Male or female patient ≥ 18 years
•Primary sjögren syndrome according of age to 2002 or 2016 classification criteria

Exclusion Criteria

•Secondary sjögren syndrome

Locations (3)

CHRU de Brest

Brest, France

CHU de LILLE

Lille, France

CHU de MONTEPELLIER

Montpellier, France

Key Dates

Start Date

November 20, 2019

Primary Completion Date

May 20, 2020

Completion Date

May 20, 2020

Last Updated

December 27, 2019

Enrollment

242

ESTIMATED participants

Conditions

Primary sjögren's Syndrome

Contacts

Valerie DEVAUCHELLE

CONTACT

2 98 34 72 64 valerie.devauchelle-pensec@chu-brest.fr

Open-Label Extension Study to Evaluate the Safety of Efgartigimod in Adult Patients With Primary Sjögren's Syndrome

NCT06203457

Primary Sjögren's Syndrome

View study

COMPLETEDPHASE1

Safety and Tolerability of IBI355 in Patients With Primary Sjogren's Syndrome

NCT06484855

Primary Sjögren's Syndrome

View study

COMPLETEDPHASE2

A Study of the Safety and Effectiveness of Efgartigimod in Patients With Primary Sjögren's Syndrome (pSS)

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: December 27, 2019Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Ultrasound Abnormalities of the Salivary Glands in Primary Sjögren's Syndrome According to the Duration of the Disease

Inclusion Criteria

Exclusion Criteria

Open-Label Extension Study to Evaluate the Safety of Efgartigimod in Adult Patients With Primary Sjögren's Syndrome

Safety and Tolerability of IBI355 in Patients With Primary Sjogren's Syndrome

A Study of the Safety and Effectiveness of Efgartigimod in Patients With Primary Sjögren's Syndrome (pSS)

Therapeutic Effect of Upadacitinib in Primary Sjögren's Syndrome

Clinical Study to Investigate the Efficacy of Orally Administered SA001 in Patients With Primary Sjögren's Syndrome

Efficacy, Safety and Immunological Evaluation of Tofacitinib in the Treatment of Primary Sjogren's Syndrome